Document Detail

Recombinant interferon alfa-2a in advanced malignant melanoma. A phase I-II study in combination with DTIC.
MedLine Citation:
PMID:  3476475     Owner:  NLM     Status:  MEDLINE    
There is a rising incidence of malignant melanoma world-wide and, despite major improvements in its early diagnosis and treatment, the 10-year death rate remains at 20-25%. Evidence that the immune system has a role in the control of melanoma growth has encouraged immunological intervention. The results of phase II trials of recombinant interferon alfa-2a in advanced melanoma justified further studies. A review of trials of various interferons used as sole agents showed an overall objective response rate of 16.3%, one-third of the responses being complete responses of long duration. The use of cimetidine together with recombinant interferon alfa-2a remains controversial. Trials of both beta- and gamma-interferons are incomplete and information on their effect in advanced melanoma is not yet available. Recombinant interferon alfa-2a in combination with chemotherapy is now being used in trials and the early results are encouraging. In a combined series from Brisbane and Newcastle, Australia involving 44 patients treated with recombinant interferon alfa-2a and DTIC, 13 objective responses including 6 complete responses have been obtained. These response rates compare favourably with those of earlier trials using interferon alone. Further work is necessary to determine the best combined dosage and method of administration for optimum immunobiological effect.
G R McLeod; D B Thomson; P Hersey
Related Documents :
9884275 - Interferon-alpha treatment of posttransplant lymphoproliferative disorder in recipients...
21273605 - Detection and significance of parametrial micrometastases in early-stage cervical cancer.
3136645 - A phase ii study of the efficacy of recombinant interferon gamma in relapsing ovarian a...
14646625 - Treatment of locoregional metastases of malignant melanomas with radiotherapy and intra...
1987845 - Factors influencing survival after pancreaticoduodenectomy for pancreatic cancer.
2549205 - Phase i clinical investigation of amonafide.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  International journal of cancer. Supplement = Journal international du cancer. Supplement     Volume:  1     ISSN:  0898-6924     ISO Abbreviation:  Int. J. Cancer Suppl.     Publication Date:  1987  
Date Detail:
Created Date:  1987-10-19     Completed Date:  1987-10-19     Revised Date:  2007-07-23    
Medline Journal Info:
Nlm Unique ID:  8710267     Medline TA:  Int J Cancer Suppl     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  31-5     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Combined Modality Therapy
Dacarbazine / adverse effects,  therapeutic use*
Dose-Response Relationship, Drug
Drug Evaluation
Interferon Type I / adverse effects,  therapeutic use*
Melanoma / therapy*
Middle Aged
Prospective Studies
Recombinant Proteins / adverse effects,  therapeutic use*
Reg. No./Substance:
0/Interferon Type I; 0/Recombinant Proteins; 4342-03-4/Dacarbazine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Management of cancer patients receiving interferon alfa-2a.
Next Document:  Further experience with recombinant interferon alfa-2a with vinblastine in metastatic renal cell car...